AD mission in the U.K.

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly £120 million ($205 million) from U.K.-based organizations for a series of research initiatives that span R&D from discovery to the clinic. Reaching the target might require international coordination to incentivize investors.

In the last few years, several governments have responded to the looming healthcare crisis in Alzheimer's disease (AD) by launching or joining public-private partnerships with pharmas, not-for-profit organizations and academic organizations (see "Dementia public-private partnerships").

The field has been held back by numerous late-stage clinical failures that prompted several pharmas to pull out and others to rethink their strategies from target selection to trial design. Clinical trials for AD are difficult because the disease progresses slowly, there are no biomarkers to indicate whether a therapeutic is working and the most widely studied target-b-amyloid (Ab)-has thus far proven fruitless.

Mike Hutton, CSO of neurodegeneration at Eli Lilly and Co., told SciBX that "dementia is a set of slowly progressing diseases, and it is very difficult to design trials that tell us if a drug is working. We don't usually know if a drug is working until we get to Phase III trials, which usually last 18 months, include more than 1,000 patients and are very expensive."

As the incidence of the disease grows with the aging population, several governments have concluded that the problem might not be solved if left to the private sector alone.

In the U.K., Prime Minister David Cameron first spoke out in March 2012

Read the full 2496 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers